Understanding the Shift: From NAFLD to Steatotic Liver Disease management

The global medical community recently underwent a significant shift in how we perceive and categorize liver conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), now stands at the forefront of public health discussions. This nomenclature change represents a fundamental transition toward identifying metabolic dysfunction as the central driver of hepatic pathology. Consequently, Steatotic Liver Disease management has become an essential competency for a wide range of clinicians, extending far beyond the walls of hepatology clinics. In Mexico, where liver diseases are the fifth leading cause of death, the prevalence of MASLD is estimated to approach 50% of the adult population. Similarly, Indian clinicians face a parallel crisis, with recent studies indicating that nearly 40% of Indian adults may be affected. This evolution in terminology encourages a more inclusive and less stigmatizing approach to diagnosis. Furthermore, it highlights the shared pathophysiological mechanisms that link liver health to obesity, type 2 diabetes, and cardiovascular risk. As we move forward, integrating these insights into daily practice will be crucial for improving long-term patient outcomes and reducing the global burden of chronic liver disease.

The Epidemiological Parallels between Mexico and India

The epidemiological landscape of MASLD reveals an alarming trend that transcends geographical boundaries. In Mexico, the condition is deeply rooted in the social and commercial determinants of health, such as the high consumption of ultra-processed foods and common genetic susceptibilities. Moreover, the prevalence of metabolic risk factors like obesity and diabetes has reached critical levels, mirroring the situation observed in the Indian subcontinent. Indian patients, however, often present a unique clinical phenotype, frequently developing metabolic dysfunction at lower body mass indices compared to Western cohorts. This lean MASLD phenomenon underscores the importance of visceral adiposity and insulin resistance over simple weight metrics. Therefore, understanding these regional nuances is vital for effective Steatotic Liver Disease management. Population-level screening and targeted interventions are necessary to address the rising mortality associated with liver-related complications. In addition, the lack of awareness among both the general public and healthcare providers often leads to delayed diagnosis. By recognizing the similarities between the Mexican and Indian health crises, medical communities can share strategies to combat these silent epidemics. Strengthening healthcare coverage and investing in research and innovation will be essential to provide equitable care for all affected individuals.

Pathophysiological Synergy: Linking Metabolism and Liver Health

A deep understanding of the pathophysiological synergy between the liver and metabolic health is foundational to modern clinical practice. Clinicians recognize MASLD as the hepatic manifestation of metabolic syndrome, characterized by a complex interplay of insulin resistance, chronic inflammation, and oxidative stress. When metabolic dysfunction occurs, the liver becomes a primary site for ectopic fat accumulation, leading to lipotoxicity and subsequent tissue damage. Consequently, patients often present with a cluster of comorbidities, including dyslipidemia, hypertension, and type 2 diabetes. These shared risk factors suggest that the clinical trajectory of liver disease is inextricably linked to cardiovascular health. Furthermore, genetic variants such as PNPLA3 appear to play a significant role in determining individual susceptibility and disease progression. For clinicians, this means that Steatotic Liver Disease management must address the systemic nature of the condition rather than focusing solely on the liver. Integrated care models that prioritize metabolic optimization can significantly slow or even reverse the progression of hepatic steatosis and fibrosis. In addition, the role of the gut-liver axis and the influence of the microbiome are emerging as critical areas of research. By targeting these multifaceted pathways, we can develop more precise and effective therapeutic interventions for our patients.

Screening and Diagnosis: Implementing Early Detection Strategies

Implementing effective screening and early detection strategies is a cornerstone of proactive healthcare. Since MASLD is often asymptomatic in its early stages, many patients remain undiagnosed until advanced fibrosis or cirrhosis has developed. Therefore, the medical community must transition toward a case-finding approach, particularly for high-risk individuals with diabetes or obesity. Primary care physicians play a pivotal role in this process, as they are the first point of contact for the majority of these patients. Tools such as the Fibrosis-4 (FIB-4) index, which utilizes common laboratory values like age, AST, ALT, and platelet count, provide a low-cost and accessible method for initial risk stratification. Additionally, abdominal ultrasonography remains a valuable first-line imaging modality to detect hepatic steatosis. However, more advanced techniques like transient elastography are often necessary to accurately assess the degree of liver stiffness and fibrosis. Integrating these diagnostic workflows into routine clinical practice can facilitate timely referrals to specialists when needed. Furthermore, educating patients about the importance of early detection and the potential for disease reversal through lifestyle modification is essential. Consequently, a systematic approach to screening can reduce the long-term burden on the national health system while improving individual patient outcomes and quality of life.

Multidisciplinary Care: A New Paradigm for Patient Outcomes

The complexity of MASLD necessitates a multidisciplinary care paradigm that brings together experts from various fields. Because the disease shares risk factors and pathophysiological mechanisms with numerous other non-communicable diseases, a siloed approach to treatment is no longer sufficient. Collaborative efforts between hepatologists, endocrinologists, cardiologists, and primary care providers are essential to provide comprehensive care. For example, managing a patient’s glycemic control and lipid profile is just as critical as monitoring their liver enzymes for successful Steatotic Liver Disease management. Moreover, nutritionists and physical therapists should be integral members of the care team, as lifestyle modification remains the primary treatment for most patients. Studies have consistently shown that even a modest weight loss of 5% to 7% can lead to a significant reduction in liver fat. Furthermore, emerging pharmacologic therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, offer promising avenues for treating both metabolic and hepatic components of the disease. By fostering a culture of multidisciplinary collaboration, we can ensure that patients receive holistic and personalized care tailored to their specific needs. This approach not only addresses the immediate hepatic concerns but also mitigates the significant cardiovascular risks associated with metabolic dysfunction, ultimately leading to better health results.

Strategic Recommendations for National Health Policy

Addressing the public health threat of steatotic liver disease requires a robust policy response at the national level. Integration of MASLD into existing non-communicable disease strategies and clinical practice guidelines is a vital step forward. Governments should strengthen multisectoral policies aimed at reducing the consumption of unhealthy foods and alcohol while promoting active lifestyles. In addition, increasing investment in healthcare infrastructure and research is necessary to improve the accessibility and quality of care. By defining a cohesive and effective public health response, we can better protect vulnerable populations and reduce the overall economic burden of liver-related illnesses. The medical community must advocate for these changes to ensure that comprehensive and equitable care becomes a reality for all patients across different socioeconomic backgrounds. Finally, improving healthcare coverage will ensure that advanced diagnostics and treatments are available to those who need them most.

Why was NAFLD renamed to MASLD?

The renaming from NAFLD to MASLD was driven by a need for more precise and inclusive medical terminology. The term "non-alcoholic" was considered stigmatizing by many patients and failed to capture the underlying metabolic drivers of the condition. MASLD, or metabolic dysfunction-associated steatotic liver disease, emphasizes that metabolic dysfunction is the core cause. This change helps clinicians focus on treating the holistic metabolic health of the patient rather than simply excluding alcohol use during the diagnosis.

What are the primary risk factors for MASLD in the Indian context?

In India, the primary risk factors for MASLD include type 2 diabetes, central obesity, and dyslipidemia. Interestingly, many Indians develop the condition at a lower body mass index, a phenomenon known as "lean MASLD." This is often linked to high visceral adiposity and significant insulin resistance despite a normal total body weight. Sedentary lifestyles and diets high in refined carbohydrates and saturated fats further exacerbate these risks across diverse urban and rural socioeconomic populations in India.

How can primary care physicians contribute to MASLD screening?

Primary care physicians are on the frontline of detecting MASLD by screening high-risk patients, particularly those with obesity or metabolic syndrome. They can utilize simple, non-invasive tools like the FIB-4 index, which relies on routine blood tests, to identify patients at risk for advanced fibrosis. By providing early education on lifestyle modifications and coordinating care with specialists, primary care providers ensure timely intervention. This proactive approach is essential for preventing the progression of the disease to cirrhosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Bautista Garín MF et al. Addressing the Public Health Threat of Steatotic Liver Disease in Mexico. Arch Med Res. 2026 Jul 09. doi: undefined. PMID: 42424718.

Duseja A, et al. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol. 2024.

Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.